The idea
An implantable pump is a small device placed inside the body, usually under the skin of the abdomen, that holds a reservoir of medicine and releases it at a controlled rate through a thin tube, called a catheter. The tube ends at the place where the drug is needed: a blood vessel, the space around the spinal cord, or the abdominal cavity. The idea is appealing because it keeps a steady supply of a drug going without daily injections or a visible device, and it can deliver a small dose directly to a target, rather than to the whole body.
The concept belongs to a broader family of implantable devices, but it differs from a pacemaker in one important way. A pacemaker runs on a battery that eventually needs replacing. A drug pump has both a power source and a drug supply, and the supply must be refilled.
Early work and who was involved
Implantable pumps emerged from the 1960s and 1970s, when advances in miniaturization, biocompatible materials and small mechanical parts made them thinkable. It is hard to name a single inventor, because several research groups and companies were working on different designs at roughly the same time. Accounts differ on details, and only the general outline is well established.
One early design used a pressure source that did not require a battery. In this approach, a chamber contained a liquid that evaporates at body temperature, producing a steady gas pressure that squeezed the drug reservoir and pushed the medicine out through a restrictor at a slow, predictable rate. A pump built on this principle was developed at a company named Infusaid, and became associated with delivering chemotherapy drugs to the liver. It was cleared for use in the United States in the early 1980s, though sources vary on the exact date.
Another approach used a battery-powered pump, often with a peristaltic mechanism, which squeezes a flexible tube in sequence to move fluid forward. These pumps could be programmed from outside the body using a radio link, so a clinician could change the dose without surgery. Programmable pumps from several manufacturers became established in the 1980s and 1990s.
Uses beyond diabetes
Insulin was only one of the early targets, and not the one that became most common. Implantable pumps found their main use in other conditions. Pumps that deliver medication to the fluid around the spinal cord have been used for severe, long-lasting spasticity, and for pain that is not controlled by other means. This route allows much smaller doses than are needed when a drug is taken by mouth, which can reduce side effects. Pumps have also been used to deliver cancer drugs regionally, as mentioned above.
These uses share one feature: the patient needs a drug continuously over a long period, and the target area is known. That fit the technology well. The details of individual treatments are a medical matter beyond the scope of this history, and nothing here is advice about any treatment.
Insulin pumps inside the body
For diabetes, researchers pursued implanted pumps in clinical studies from the late 1970s through the 1990s and beyond. The concept was to place a pump under the skin of the abdomen with a catheter that delivered insulin into the abdominal cavity, or in some trials into a vein. Insulin delivered into the abdominal cavity is absorbed faster and more consistently than insulin from under the skin, and it resembles the way the pancreas releases insulin into the liver circulation more closely. Some early groups, including researchers in the United States and Europe, reported that the approach could improve blood sugar control for certain patients, though study sizes were small and results varied.
A pump of this type typically held a reservoir of concentrated insulin that needed to be refilled every few weeks or months by inserting a needle through the skin into a refill port. The patient controlled meal doses with an external remote device. One manufacturer, Medtronic MiniMed, ran trials for years, but the product did not reach widespread commercial use in the United States, and development eventually slowed.
Engineering problems
The reasons were mostly practical. Several problems stood out in the published literature:
- Catheter blockage. Insulin can clump or form deposits, and tissue can grow over the catheter tip, reducing delivery without the patient knowing.
- Insulin stability. Insulin kept at body temperature for weeks has to remain active and not precipitate, which required special formulations.
- Refilling. Each refill required a trained clinician, and errors could be dangerous.
- Sensing. Without a reliable implanted glucose sensor, the pump could only follow a programmed schedule and the patient’s own commands, so it was not a true automatic system.
- Surgery and cost. Implantation and replacement required surgery, and the devices were expensive compared with external pumps, which were improving rapidly.
External pumps and later wearable sensor systems developed in a direction that avoided most of these problems, since they were easier to adjust, replace and remove.
Where the idea stands
Implantable pumps remain a tool for specific, selected patients, mainly in pain and spasticity care. For diabetes, the implanted pump is best described as a technology that proved the principle but stayed a niche, partly because other approaches advanced faster. Researchers still study intraperitoneal insulin delivery, and some see it as a possible component of future automated systems.
The technology offers a good example of how a promising invention can find its best use in an unexpected field. It also shows the gap between a working prototype and a durable, safe, affordable medical product, a gap that often takes decades to close. As with all medical devices, benefits and risks depend on the individual, and this article is a historical overview rather than guidance.